High serum level of interleukin‑6 is linked with dyslipidemia in oral lichen planus

Toader,Mihaela Paula; Taranu,Tatiana; Constantin,Maria Magdalena; Olinici,Doinita; Mocanu,Madalina; Costan,Victor Vlad; Toader,Stefan

doi:10.3892/etm.2021.10419

High serum level of interleukin‑6 is linked with dyslipidemia in oral lichen planus

Authors:
- Mihaela Paula Toader
- Tatiana Taranu
- Maria Magdalena Constantin
- Doinita Olinici
- Madalina Mocanu
- Victor Vlad Costan
- Stefan Toader
View Affiliations

Affiliations: Department of Oral Dermatology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, Department of Dermatology, ‘Carol Davila’ University of Medicine and Pharmacy, 020125 Bucharest, Romania, Department of Morphofunctional Sciences 2, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, Department of Oral and Maxillofacial Surgery, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, Department of Pathophysiology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania
Published online on: July 13, 2021 https://doi.org/10.3892/etm.2021.10419
Article Number: 987
Copyright: © Toader et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral lichen planus (OLP) is a complex chronic inflammatory disorder in which autocytotoxic CD8⁺ T cells, locally present in the affected tissue, induce basal keratinocyte apoptosis, through the release of several cytokines, such as interleukin‑6 (IL‑6). IL‑6 is a proinflammatory cytokine that is related to alterations in lipid metabolism in psoriasis patients. Impaired lipid metabolism together with high serum levels of triglycerides have been found in association with OLP. However, the correlation between serum levels of IL‑6 and dyslipidemia has not yet been studied in this disorder. The present study aimed to demonstrate the association between OLP, systemic inflammation through increased release of inflammation mediators such as IL‑6 and alteration of lipid metabolism, in order to support the concept of OLP as a marker of systemic inflammation and a potential risk factor of cardiovascular morbidities. For this purpose, we designed a case‑control study using a cohort of 18 patients with different clinical forms of OLP compared with 18 control group patients with other oral conditions, to identify a potential correlation between serum levels of IL‑6 and serum lipid levels. High plasma serum levels of IL‑6 were found to be correlated with cholesterol, high density lipoprotein cholesterol and triglyceride serum levels in the patients with OLP. There was a significant association between erosive and atrophic clinical forms of OLP and the pathological serum values of IL‑6 and triglycerides, respectively, making these two parameters good predictive factors of the clinical form of OLP. Further studies of other biomarkers of systemic inflammation using larger cohorts of OLP patients are necessary in order to consider LP as a marker of systemic inflammation and to support the screening of these patients for lipid metabolism changes and treatment with specific antagonists in order to prevent cardiovascular events.

View Figures

View References

1	De Rossi SS and Ciarrocca K: Oral lichen planus and lichenoid mucositis. Dent Clin North Am. 58:299–313. 2014.PubMed/NCBI View Article : Google Scholar
2	Popovska M, Radojkova-Nikolovska V, Minovska A, Agop Forna D, Muratovska I and Forna NC: Etiopathogenic biochemical mechanism involved in oral lichen planus. Rev Chim. 66:1786–1790. 2015.
3	Ianosi SL, Forsea AM, Lupu M, Ilie MA, Zurac S, Boda D, Ianosi G, Neagoe D, Tutunaru C, Popa CM and Caruntu C: Role of modern imaging techniques for the in vivo diagnosis of lichen planus. Exp Ther Med. 17:1052–1060. 2019.PubMed/NCBI View Article : Google Scholar
4	Lupu M, Caruntu A, Caruntu C, Boda D, Moraru L, Voiculescu V and Bastian A: Non-invasive imaging of actinic cheilitis and squamous cell carcinoma of the lip. Mol Clin Oncol. 8:640–646. 2018.PubMed/NCBI View Article : Google Scholar
5	Lupu M, Căruntu A, Moraru L, Voiculescu VM, Boda D, Tanase C and Căruntu C: Non-invasive imaging techniques for early diagnosis of radiation-induced squamous cell carcinoma of the lip. Rom J Morphol Embryol. 59:949–953. 2018.PubMed/NCBI
6	Calenic B, Greabu M, Caruntu C, Nicolescu MI, Moraru L, Surdu-Bob CC, Badulescu M, Anghel A, Logofatu C and Boda D: Oral keratinocyte stem cells behavior on diamond like carbon films. Rom Biotechnol Lett. 21:11914–11922. 2016.
7	Boda D, Docea AO, Calina D, Ilie MA, Caruntu C, Zurac S, Neagu M, Constantin C, Branisteanu DE, Voiculescu V, et al: Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues. Int J Oncol. 52:637–655. 2018.PubMed/NCBI View Article : Google Scholar
8	Boda D, Neagu M, Constantin C, Voinescu RN, Caruntu C, Zurac S, Spandidos DA, Drakoulis N, Tsoukalas D and Tsatsakis AM: HPV strain distribution in patients with genital warts in a female population sample. Oncol Lett. 12:1779–1782. 2016.PubMed/NCBI View Article : Google Scholar
9	Solomon I, Voiculescu VM, Caruntu C, Lupu M, Popa A, Ilie MA, Albulescu R, Caruntu A, Tanase C, Constantin C, et al: Neuroendocrine factors and head and neck squamous cell carcinoma: An affair to remember. Dis Markers. 2018(9787831)2018.PubMed/NCBI View Article : Google Scholar
10	Giuliani M, Troiano G, Cordaro M, Corsalini M, Gioco G, Lo Muzio L, Pignatelli P and Lajolo C: Rate of malignant transformation of oral lichen planus: A systematic review. Oral Dis. 25:693–709. 2019.PubMed/NCBI View Article : Google Scholar
11	Aniyan KY, Guledgud MV and Patil K: Alterations of serum lipid profile patterns in oral lichen planus patients: A case-control study. Contemp Clin Dent. 9 (Suppl 1):S112–S121. 2018.PubMed/NCBI View Article : Google Scholar
12	Sezer E, Ozugurlu F, Ozyurt H, Sahin S and Etikan I: Lipid peroxidation and antioxidant status in lichen planus. Clin Exp Dermatol. 32:430–434. 2007.PubMed/NCBI View Article : Google Scholar
13	Lai YC, Yew YW and Schwartz RA: Lichen planus and dyslipidemia: A systematic review and meta-analysis of observational studies. Int J Dermatol. 55:e295–e304. 2016.PubMed/NCBI View Article : Google Scholar
14	Ozbagcivan O, Akarsu S, Semiz F and Fetil E: Comparison of serum lipid parameters between patients with classic cutaneous lichen planus and oral lichen planus. Clin Oral Investig. 24:719–725. 2020.PubMed/NCBI View Article : Google Scholar
15	Arias-Santiago S, Eisman AB, Fernandez JA, Girón-Prieto MS, Gutiérrez-Salmerón MT, García Mellado V and Naranjo-Sintes R: Cardiovascular risk factors in patients with lichen planus. Am J Med. 124:543–548. 2011.PubMed/NCBI View Article : Google Scholar
16	Esteve E, Ricart W and Fernández-Real JM: Dyslipidemia and inflammation: An evolutionary conserved mechanism. Clin Nutr. 24:16–31. 2005.PubMed/NCBI View Article : Google Scholar
17	Krishnamoorthy B, Suma GN, Mamatha NS, Sowbhagya MB and Komali Garlapati: Lipid profile and metabolic syndrome status in patients with oral lichen planus, oral lichenoid reactions and healthy individuals attending a dental college in Northern India - a descriptive study. J Clin Diagn Res. 8:ZC92–ZC95. 2014.PubMed/NCBI View Article : Google Scholar
18	Hotamisigil GS: Inflammation and metabolic disorders. Nature. 444:860–867. 2006.PubMed/NCBI View Article : Google Scholar
19	Scheller J, Chalaris A, Schmidt-Aras D and Rose-John S: The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Act. 1813:878–888. 2011.PubMed/NCBI View Article : Google Scholar
20	Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF and Achong MK: IL6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 101:311–320. 1998.PubMed/NCBI View Article : Google Scholar
21	Paquet P and Piérard GE: Interleukin-6 and the skin. Int Arch Allergy Immunol. 109:308–317. 1996.PubMed/NCBI View Article : Google Scholar
22	Lipsky PE: Interleukin-6 and rheumatic diseases. Arthritis Res Ther. 8 (Suppl 2)(S4)2006.PubMed/NCBI View Article : Google Scholar
23	Khishimoto T: Interleukin-6: Discovery of a pleiotropic cytokine. Arthritis Res Ther. 8 (Suppl 2)(S2)2006.PubMed/NCBI View Article : Google Scholar
24	Patil S, Roopa SR, Sanketh DS, Sarode SC and Sarode GS: A universal diagnostic criteria for oral lichen planus: An exigency! Int J Contemp Dental Medical Rev. 1–4. 2014.
25	Baykal L, Arıca DA, Yaylı S, Örem A, Bahadır S, Altun E and Yaman H: Prevalence of metabolic syndrome in patients with lichen planus. A case-control study. Am J Clin Dermatol. 16:439–445. 2005.PubMed/NCBI View Article : Google Scholar
26	Romero MA, Seoane J, Varela-Centelles P, Diz-Dios P and Garcia-Pola MJ: Prevalence of diabetes mellitus amongst oral lichen planus patients. Clinical and pathological characteristics. Med Oral. 7:121–129. 2002.PubMed/NCBI(In English, Spanish).
27	Eisen D: The clinical features, malignant potential and systemic associations of oral lichen planus: A study of 723 patients. J Am Acad Dermatol. 46:207–214. 2002.PubMed/NCBI View Article : Google Scholar
28	Lopez-Jornet P, Alonso CF and Rodríguez-Martines MA: Alterations in serum lipid profile patterns in oral lichen planus. A cross-sectional study. Am J Clin Dermatol. 13:399–404. 2012.PubMed/NCBI View Article : Google Scholar
29	Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB and Gelfand JM: Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 55:829–835. 2006.PubMed/NCBI View Article : Google Scholar
30	Sommer DM, Jenish S, Suchan M, Christophers E and Weichenthal M: Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 298:321–328. 2006.PubMed/NCBI View Article : Google Scholar
31	Grechin C, Solovăstru LG, Vâță D, Pătrașcu AI, Grăjdeanu AI and Porumb-Andrese E: Inflammatory marker alteration in response to systemic therapies in psoriasis. Exp Ther Med. 20:42–46. 2020.PubMed/NCBI View Article : Google Scholar
32	Boda D and Dehelean C: Immuno-dermatological processes involved in chronic skin diseases: Highlights of the Second Conference of the Romanian Society for Immuno-Dermatology, Bucharest. Exp Ther Med. 18:873–874. 2018.PubMed/NCBI View Article : Google Scholar
33	Narazaki M and Kishimoto T: The two-faced cytokine IL-6 in host defenseand diseases. Int J Mol Sci. 19(3528)2018.PubMed/NCBI View Article : Google Scholar
34	Pauli N, Puchałowicz K, Kuligowska A, Krzystolik A, Dziedziejko V, Safranow K, Rać M, Chlubek D and Rać ME: Associations between IL-6 and echo-parameters in patients with early onset coronary artery disease. Diagnostics (Basel). 9(189)2019.PubMed/NCBI View Article : Google Scholar
35	Gabay C: Interleukin-6 and chronic inflammation. Arthritis Res Ther. 8 (Suppl 2)(S3)2006.PubMed/NCBI View Article : Google Scholar
36	Tanaka T, Narazaki M, Masuda K and Kishimoto T: Interleukin-6: Pathogenesis and treatment of autoimmune inflammatory diseases. Inflam Regeneratin. 33:54–65. 2013.
37	Tanaka T, Narazaki M and Kishimoto T: Therapeutic targeting of interleukin-6 receptor. Ann Rev Pharmacol Toxicol. 52:199–219. 2012.PubMed/NCBI View Article : Google Scholar
38	Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, Ohlsson C and Jansson JO: Interleukin-6 deficient mice develop mature-onset obesity. Nat Med. 8:75–79. 2002.PubMed/NCBI View Article : Google Scholar
39	Matthews VB, Allen TL, Risis S, Chan MH, Henstridge DC, Watson N, Zaffino LA, Babb JR, Boon J, Meikle PJ, et al: Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia. 53:2431–2441. 2010.PubMed/NCBI View Article : Google Scholar